Assay Report
Methods · Standard Curves · QC · Results
Ultra-sensitive single-molecule digital immunoassay services for quantifying low-abundance cytokines, chemokines, and inflammatory mediators in plasma, serum, CSF, tears, and cell culture supernatants down to sub-picogram per milliliter limits.
When critical immune mediators circulate at basal levels below the quantification limits of conventional plate ELISAs or standard multiplex platforms, Simoa digital single-molecule counting resolves baseline trajectories and subtle pharmacodynamic shifts. Creative Proteomics establishes fit-for-purpose sampling frameworks and delivers high-precision research datasets across preclinical immunology and pharmacology pipelines.
Establishing standardized bioanalytical parameters to ensure high data integrity across dynamic inflammatory cascades.
| Planning Dimension | Core Parameters Defined Collaboratively | Impact on Data Integrity & Interpretation |
|---|---|---|
| Kinetic Sampling Windows | Hyper-acute phase (0–4h: TNF-α, IL-6), peak wave (6–24h: IFN-γ, IL-10), or resolution (Day 2–7+) | Captures transient primary response peaks before systemic hepatic and renal clearance. |
| Baseline & Vehicle Controls | Pre-treatment intra-individual baselines vs. vehicle-treated parallel control cohorts | Separates genuine drug-mediated immunomodulation from stress- or circadian-induced fluctuations. |
| Target Signature Scoping | Focused core mediators (e.g., IL-1β/IL-6/TNF-α/IL-10) + contextual chemokines (MCP-1, IL-8) | Delivers a high-resolution, interpretable signature while avoiding broad, uninformative data bloat. |
| Micro-Volume Allocation | 15 μL net volume per well, duplicate verification reserve, and orthogonal follow-up | Conserves longitudinal small-animal biofluids across multi-week drug evaluation regimens. |
| Plate Layout & Balancing | Randomizing treatment arms, dose escalations, and longitudinal timepoints across analytical runs | Eliminates confounding between true experimental treatment effects and run-to-run bioanalytical variance. |
Validated single-analyte and multiplex digital immunoassay configurations for ultra-sensitive cytokine quantification.
| Target Analyte | Biomarker Category | Functional LLOQ (pg/mL) | Dynamic Range (pg/mL) | Primary Research & Disease Applications |
|---|---|---|---|---|
| IL-6 | Proinflammatory / Cytokine Release | 0.010 | 0.010 – 1,000 | Cytokine release syndrome (CRS) monitoring, acute phase response, autoimmune flares, neuroinflammation |
| IL-1β | Inflammasome / Acute Pyrogen | 0.020 | 0.020 – 500 | NLRP3 inflammasome activation, autoinflammatory models, metabolic inflammation |
| TNF-α | Master Proinflammatory Mediator | 0.050 | 0.050 – 1,200 | Early immune activation, sepsis models, anti-TNF therapeutic efficacy tracking |
| IL-10 | Anti-Inflammatory / Counter-Regulatory | 0.030 | 0.030 – 800 | Immune suppression, regulatory T-cell response, post-inflammatory resolution |
| IFN-γ | Type 1 Immunity / T-Cell Activation | 0.040 | 0.040 – 1,000 | Th1 polarization, T-cell engager / CAR-T potency, viral response modeling |
| IL-2 | T-Cell Proliferation & Survival | 0.050 | 0.050 – 1,000 | Immunotherapy pharmacodynamics, T-cell activation kinetics, Treg homeostasis |
| IL-4 | Type 2 Immunity / Th2 Cytokine | 0.020 | 0.020 – 500 | Allergic inflammation, Th2 skewing, humoral B-cell activation, atopic disease |
| IL-5 | Eosinophil Activation & Maturation | 0.030 | 0.030 – 500 | Eosinophilic asthma models, parasite defense, allergic airway inflammation |
| IL-13 | Type 2 Effector / Tissue Remodeling | 0.030 | 0.030 – 600 | Fibrotic remodeling, mucus hypersecretion, Type 2 allergic inflammation |
| IL-17A | Th17 / Neutrophil Recruitment | 0.050 | 0.050 – 1,000 | Autoimmune pathogenesis (psoriasis, RA, IBD), mucosal barrier defense |
| MCP-1 (CCL2) | Monocyte / Macrophage Chemokine | 0.050 | 0.050 – 2,000 | Macrophage trafficking, chronic tissue inflammation, vascular inflammation |
| IL-8 (CXCL8) | Neutrophil Chemotaxis & Activation | 0.020 | 0.020 – 1,500 | Acute tissue injury, neutrophil infiltration, tumor microenvironment modeling |
Evaluating analytical performance, multiplex capacity, and detection boundaries across bioanalytical platforms for cytokine and inflammation programs.
| Decision Dimension | Conventional Plate ELISA | Luminex xMAP Multiplex | MSD ECL Platform | Quanterix Simoa Focused Measurement (Our Service) |
|---|---|---|---|---|
| Primary Role | Routine single-analyte work | Broad multi-pathway discovery | Multiplexing across complex matrices | High-sensitivity low-abundance quantification |
| Best-Fit Analytical Scenario | Comfortably in pg/mL–ng/mL range | Broad profiling across dozens of targets | Validated 10-plex in CSF / lysates | Low baseline, serial kinetics, scarce micro-fluids |
| Multiplex Strategy | Singleplex (1 analyte/well) | High Multiplex (Up to 50–100 plex) | Medium Multiplex (1–10 plex) | Focused Low-Plex (1–4 target configuration) |
| Typical LLOQ Range | 10.0 – 50.0 pg/mL | 1.0 – 10.0 pg/mL | 1.0 – 5.0 pg/mL | 0.01 – 0.50 pg/mL (Sub-pg/mL / fg/mL) |
| Sample Allocation | 100 μL per individual target | Shared 25–50 μL volume | 25 μL per 10-plex well | Preserves scarce samples (15 μL net volume) |
| Linear Dynamic Range | 2.0 – 2.5 logs | 3.0 – 3.5 logs | 4.0 – 5.0 logs | >4.5 logs (Poisson digital + Analog) |
| Data Continuity | Standard historical data | Broad cross-cohort screening | Robust lot-to-lot continuity | Paired pilot subset establishes bridge |
Absolute cytokine concentrations often exhibit numerical offsets across platforms because antibody clones, calibrator constructs, incubation kinetics, matrix dilution factors, and detection chemistries differ. When transitioning a longitudinal program from ELISA, Luminex, or MSD to Simoa, representative paired samples should be analyzed across both methods to establish a validated conversion algorithm, ensuring longitudinal dataset continuity across multi-year drug discovery campaigns.
Bioanalytical parameters established according to rigorous fit-for-purpose biomarker validation guidelines.
Seamless Poisson-to-analog calibration spanning sub-pg/mL baselines to 1,000+ pg/mL storm-level surges without manual re-dilution.
Formulation-level blocking reagents eliminating non-specific human anti-mouse antibodies (HAMA) and rheumatoid factor interference.
Rigorous spike-and-recovery testing confirming stability of labile inflammatory interleukins across repeated thermal cycles in biological matrices.
Specimens received on dry ice are barcode-logged, assessed for hemolysis/lipemia, and cataloged into monitored -80°C storage.
Automated liquid handling performs 1:4 sample dilution in matrix-matched assay diluent supplemented with heterophilic blockers.
Dye-encoded paramagnetic beads capture target cytokines, followed by biotinylated detector binding and SBG enzyme labeling.
Bead-enzyme complexes are loaded onto optical Simoa discs with 216,000 femtoliter wells, sealed with oil, and imaged for digital enzyme counting (AEB).
Average Enzymes per Bead (AEB) values are fitted against calibration curves to output absolute pg/mL concentrations and QC statistics.
Standardized pre-analytical protocols to ensure cytokine stability and eliminate matrix-induced suppression.
| Pre-Analytical Parameter | Why It Matters for Low-Abundance Cytokines | Intake Specification & Recommendation |
|---|---|---|
| Anticoagulant Selection | Certain cytokines (e.g., IL-1β, TNF-α) are sensitive to tube additives; heparin can cause charge-based aggregation. | K2-EDTA plasma is strongly preferred; serum is acceptable if clotted for 30–60 min at RT and promptly centrifuged. |
| Centrifugation Timing | Platelet activation and cellular lysis release intracellular cytokines (e.g., PDGF, TGF-β, IL-1β), artificially elevating baselines. | Centrifuge at 2,000 × g for 15 min at 4°C within 60 minutes of collection; harvest cell-free supernatant. |
| Freeze-Thaw Control | Cytokines undergo conformational degradation and aggregation upon repeated temperature cycling. | Aliquot immediately into polypropylene cryovials; store at -80°C; ship strictly on dry ice (minimum 5–8 kg). |
| Sample Net Volume | Single-molecule digital counting requires minimal specimen input, conserving small-animal biofluids. | 15 μL net volume per well (30–50 μL recommended for duplicate verification and reserve). |
| Cell Supernatant Context | Media additives (FBS, phenol red, stimulation cocktails) influence baseline signals and matrix parallelism. | Submit unconditioned baseline media controls alongside experimental supernatants. |
Applying ultra-sensitive single-molecule cytokine measurements across preclinical discovery and safety evaluation.
Ultra-sensitive early detection of IL-6, IFN-γ, and TNF-α surges in preclinical immunotherapy safety and cytokine release evaluations.
Quantify resting baseline inflammatory tone in healthy control and sham cohorts without ex vivo artificial hyper-stimulation.
Monitor acute inflammatory flares and therapeutic resolution in collagen-induced arthritis (CIA) and colitis mouse models.
Measure ultra-trace cytokine gradients in tumor interstitial fluid, fine-needle aspirates, and micro-dialysates.
Generate high-resolution time-course release and clearance curves (0–24h) in rodent systemic inflammation models.
Establish precise dose-response inhibition curves for novel JAK inhibitors, biologics, and small molecules against basal targets.
quality-controlled bioanalytical documentation and PhD-level consultation for every testing project.
Landmark peer-reviewed studies demonstrating single-molecule cytokine sensitivity and translational study designs.
Study Design Takeaway: Establishes the foundational physics of digital Poisson single-molecule enzyme counting in femtoliter microwells, demonstrating up to 1000-fold sensitivity gains over conventional ELISA.
Study Design Takeaway: Demonstrates robust single-molecule quantification of basal cytokines in human plasma and establishes practical method-bridging parameters against legacy multiplex systems.
Study Design Takeaway: Highlights the critical importance of sub-picogram detection limits in mapping subtle, longitudinal post-viral inflammatory resolution and cytokine networks.
Study Design Takeaway: Validates the precision, zero optical crosstalk, and multi-analyte resolution of dye-encoded magnetic beads for multiplex digital cytokine arrays.
Addressing common bioanalytical and project planning inquiries.
Cytokines with low circulating basal levels in healthy or non-stimulated states benefit most from Simoa. These include IL-1β, IL-6, IL-4, IL-5, IL-13, and IFN-γ, which circulate at 0.02–1.0 pg/mL in normal blood. While conventional ELISA yields high non-detectable rates (<LLOQ) for these markers, Simoa delivers 100% quantifiable concentration values.
Simoa combines high-affinity monoclonal capture/detector pairs with automated high-stringency magnetic bead washing and digital single-molecule counting. Non-specific background produces negligible enzyme activity in femtoliter microwells. Furthermore, all assays utilize matrix-matched diluents supplemented with heterophilic blocking reagents and are validated for dilution linearity.
The standard protocol requires only 15 μL of neat sample volume per well (which is diluted 1:4 on-board to a 60 μL working volume). We recommend providing 30–50 μL total volume to support dead volume and duplicate verification. K2-EDTA plasma is strongly preferred; heparin tubes should be avoided due to polyanionic interference.
Choose Simoa when measuring basal or subtle low-abundance targets (sub-pg/mL) in blood or micro-samples (15 μL) where high sensitivity is the primary project bottleneck. Choose MSD for high-abundance matrices (cell culture supernatants, CSF, lysates) or validated 10-plex panels with wide dynamic ranges. Choose Luminex for broad exploratory discovery across 50–100 simultaneous targets.
Cross-platform comparisons should be treated as a formal method bridging exercise. While relative group rankings and fold-changes correlate tightly (r > 0.95), variations in calibrator constructs, antibody affinities, and dilution factors introduce minor absolute numerical offsets. We provide paired bridging studies to establish mathematical conversion algorithms for long-term programs.
No. All cytokine bioanalysis services provided by Creative Proteomics are strictly for Research Use Only (RUO). They are intended for preclinical drug discovery, animal disease models, translational research cohorts, and in vitro cellular characterization, and are not intended for clinical diagnostic or patient management procedures.
Demo Assay Report
Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.
Online Inquiry
×